Physician profile
Xiaofan Li
NPI 1962631085
$1,854.05
in general payments reported to CMS, 2019-2025
14 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $304 · 2022: $515 · 2023: $466 · 2024: $307 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $817 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.63 |
| Education | $218.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $723.83 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $314.17 | 2021-2025 | Ingrezza |
| Abbvie INC. | $171.02 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $139.86 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.47 | 2021-2025 | Caplyta |
| Alkermes, INC. | $104.17 | 2021-2024 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $84.17 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $50.73 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $31.47 | 2022-2023 | Abilify Maintena |
| Merck Sharp & Dohme LLC | $27.75 | 2022-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $26.78 | 2021 | |
| Vanda Pharmaceuticals INC. | $25.61 | 2021-2022 | |
| Axsome Therapeutics, INC. | $13.18 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $12.84 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaofan Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.